中国原发性肝癌临床分期预测肝癌肝移植预后的临床研究

Prediction of prognosis of liver transplantation for primary liver carcinoma by its clinical staging in China

目的评价'中国原发性肝癌临床分期'对肝癌肝移植疗效的预测价值.方法对1993年4月至2003年1月我科59例采用肝移植治疗的肝癌病人临床资料进行回顾性分析,按中国原发性肝癌临床分期原则进行分期,比较各期间肝癌肝移植疗效.结果Ⅰb、Ⅱa、Ⅱb、Ⅲa和Ⅲb期移植术后1年生存率分别为83.33%、66.67%、50.00%、35.71%和16.67%,各期间术后累计生存率有统计学差异(P<0.01);Ⅰb ～Ⅱb 和Ⅲa～Ⅲb 期移植术后1年生存率分别为66.67%和25.00%,2年生存率分别为45.71%和25.00%,两组间术后累计生存率有统计学差异(P<0.05).结论中国原发性肝癌临床分期适用于肝癌肝移植术前分期.

Objective To assess the prognostic value of the clinical staging of primary liver carcinoma (PLC) for patients receiving liver transplantation in China. Methods The clinical data of 59 patients receiving liver transplantation for PLC between April 1993 and January 2003 in China were retrospectively analyzed. Meanwhile, the 59 patients were classified by the clinical staging of PLC and the curative efficacy of the liver transplantation was compared among patients with different clinical stages. Results The 1-year survival rate after liver transplantation was 83.33%, 66.67%, 50.00%, 35.71% and 16.67% for PLC of grade Ⅰb, Ⅱa, Ⅱb, Ⅲa and Ⅲb, respectively, and the difference was statistically significant (P<0.01). The 1- and 2-year survival rates were 66.67% and 45.71% for grade Ⅰb~Ⅱb and 25.00% and 25.00% for grade Ⅲa~Ⅲb, respectively. There was significant difference in total survival rate between these 2 groups (P<0.05). Conclusions The clinical staging of PLC in China is proper for pre-procedure staging of cases undergoing liver transplantation for the carcinoma.